Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

被引：5

作者：

Okada, Takuro ^{[1
,7
]}

Matsuki, Takashi ^{[2
]}

Fushimi, Chihiro ^{[3
]}

Okamoto, Isaku ^{[1
]}

Sato, Hiroki ^{[1
]}

Kondo, Takahito ^{[4
]}

Tokashiki, Kunihiko ^{[1
]}

Ito, Tatsuya ^{[1
]}

Masubuchi, Tatsuo ^{[3
]}

Tada, Yuichiro ^{[3
]}

Miura, Kouki ^{[3
]}

Hanyu, Kenji ^{[3
]}

Omura, Go ^{[5
]}

Takahashi, Hideki ^{[6
]}

Yamashita, Taku ^{[2
]}

Oridate, Nobuhiko ^{[6
]}

Tsukahara, Kiyoaki ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[2] Kitasato Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Sagamihara, Japan

[3] Int Univ Hlth & Welf Mita Hosp, Dept Head & Neck Oncol & Surg, Tokyo, Japan

[4] Tokyo Med Univ, Hachioji Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[5] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan

[6] Yokohama City Univ, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Japan

[7] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Shinju Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 10期

关键词：

Nivolumab; squamous cell carcinoma; head and neck; platinum-refractory; platinum-sensitive; INVESTIGATORS CHOICE; OPEN-LABEL; THERAPY; CHEMOTHERAPY; CETUXIMAB; CANCER;

D O I：

10.21873/anticanres.15996

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC.

引用

页码：4907 / 4912

页数：6

共 18 条

[1]

[Anonymous], 2010, Common Terminology Criteria for Adverse Events (CTCAE)

[2] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[5] Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use [J].

Ferris, Robert L. ;

Licitra, Lisa ;

Fayette, Jerome ;

Even, Caroline ;

Blumenschein, George, Jr. ;

Harrington, Kevin J. ;

Guigay, Joel ;

Vokes, Everett E. ;

Saba, Nabil F. ;

Haddad, Robert ;

Ramkumar, Shanmugasundaram ;

Russell, Jeffery ;

Brossart, Peter ;

Tahara, Makoto ;

Colevas, A. Dimitrios ;

Concha-Benavente, Fernando ;

Lynch, Mark ;

Li, Li ;

Gillison, Maura L. .

CLINICAL CANCER RESEARCH, 2019, 25 (17) :5221-5230

[6] Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [J].

Ferris, Robert L. ;

Blumenschein, George, Jr. ;

Fayette, Jerome ;

Guigay, Joel ;

Colevas, A. Dimitrios ;

Licitra, Lisa ;

Harrington, Kevin J. ;

Kasper, Stefan ;

Vokes, Everett E. ;

Even, Caroline ;

Worden, Francis ;

Saba, Nabil F. ;

Iglesias Docampo, Lara Carmen ;

Haddad, Robert ;

Rordorf, Tamara ;

Kiyota, Naomi ;

Tahara, Makoto ;

Lynch, Mark ;

Jayaprakash, Vijayvel ;

Li, Li ;

Gillison, Maura L. .

ORAL ONCOLOGY, 2018, 81 :45-51

[7] Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma [J].

Hori, Ryusuke ;

Shinohara, Shogo ;

Kojima, Tsuyoshi ;

Kagoshima, Hiroki ;

Kitamura, Morimasa ;

Tateya, Ichiro ;

Tamaki, Hisanobu ;

Kumabe, Yohei ;

Asato, Ryo ;

Harada, Hiroyuki ;

Kitani, Yoshiharu ;

Tsujimura, Takashi ;

Honda, Keigo ;

Ichimaru, Kazuyuki ;

Omori, Koichi .

CANCERS, 2019, 11 (09)

[8] PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer [J].

Ito, Tatsuya ;

Okamoto, Isaku ;

Tokashiki, Kunihiko ;

Sato, Hiroki ;

Okada, Takuro ;

Yamashita, Gai ;

Nagao, Toshitaka ;

Hirai, Hideaki ;

Saigusa, Natsuki ;

Tsukahara, Kiyoaki .

ANTICANCER RESEARCH, 2022, 42 (03) :1547-1554

[9] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[10] A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 [J].

Kiyota, Naomi ;

Hasegawa, Yasuhisa ;

Takahashi, Shunji ;

Yokota, Tomoya ;

Yen, Chia-Jui ;

Iwae, Shigemichi ;

Shimizu, Yasushi ;

Hong, Ruey-Long ;

Goto, Masahiro ;

Kang, Jin-Hyoung ;

Li, Wing Sum Kenneth ;

Ferris, Robert L. ;

Gillison, Maura ;

Namba, Yoshinobu ;

Monga, Manish ;

Lynch, Mark ;

Tahara, Makoto .

ORAL ONCOLOGY, 2017, 73 :138-146

← 1 2 →